Alpha Teknova, Inc. (TKNO)

Alpha Teknova's stock (TKNO) has experienced a significant decline over the past six months. In late March 2026, the stock was trading around $2.71, a decrease of approximately 28.7% since January 1, 2026. Key events impacting the stock price include the release of financial results for Q4 and full year 2025, Q3 2025, and Q1 2025. In March 2026, CEO Stephen Gunstream and CFO Matthew Lowell acquired shares, suggesting confidence from company executives.

While no explicit statements about demand seasonality for Alpha Teknova's products and services were found, the company's business is tied to the life sciences market, including pharmaceutical and biotechnology companies, and academic research. Demand is driven by ongoing research, drug discovery, and the development and commercialization of novel therapies, vaccines, and molecular diagnostics. The company is well-positioned to benefit from the increasing use of mRNA vaccines and therapies. Alpha Teknova's diversified customer base and exposure to growing markets suggest a generally stable and growing demand, rather than significant seasonal fluctuations.

Alpha Teknova is a life sciences tools and reagents company providing critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its major product categories include lab essentials, which are chemical formulations used in biological research and drug discovery, and clinical solutions, which are custom products vital for the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company offers pre-poured media plates, liquid microbial culture media and supplements, and molecular biology reagents. Alpha Teknova serves a diverse customer base in the life sciences market.

Alpha Teknova derives key revenue from the United States and has a significant customer presence across the United States, Europe, and Asia. The company is headquartered in Hollister, California, where most of its products are manufactured.

Alpha Teknova maintains a strong brand reputation, particularly emphasizing customer service and product quality. The company reported approximately 95% on-time product delivery in 2025. Management highlights high customer loyalty, with roughly 95% annual retention among larger accounts. They are recognized for their expertise in complex, custom chemical formulation manufacturing, quality and regulatory expertise, and industry-leading delivery times for custom products.

Alpha Teknova's ownership is distributed among institutional shareholders, individual insiders, and retail investors. Key institutional shareholders include Roubaix Capital, LLC, Balyasny Asset Management Llc, UBS Group AG, BlackRock, Inc., Vanguard Group Inc, Conestoga Capital Advisors, LLC, and Royce & Associates Lp. Telegraph Hill Partners IV LP is the largest individual shareholder, owning 47.81% of the company. Individual insiders own approximately 10.3% of the company.